AnGes MG to Market and Distribute BioMarin's Naglazyme in Japan.Tokyo, Japan, Jan 29, 2007 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - AnGes MG, Inc. announced on January 22 that it has entered into a Marketing and Distribution Agreement with California-based BioMarin Pharmaceutical granting AnGes exclusive rights to market and distribute Naglazyme(TM) (galsulfase) for patients with the genetic disease mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome Ma·ro·teaux-La·my syndrome n. An inherited defect in mucopolysaccharide metabolism characterized by excretion of dermatan sulfate in the urine, retarded growth, lumbar kyphosis, sternal protrusion, knock-knee, and usually enlargement of the liver and ) in Japan. Naglazyme is a normal variant form of arylsulfatase B IUPAC IUPAC: see International Union of Pure and Applied Chemistry. name N-acetylgalactosamin 4-sulfatase) that is lacking in mucopolysaccharidosis VI patients. It is produced by recombinant DNA technology recombinant DNA technology Recombining of DNA molecules from two different species that are inserted into a host organism to produce new genetic combinations that are of value to science, medicine, agriculture, or industry. at BioMarin. The U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) approved the therapy in May 2005 and subsequently, the European Commission (EC) approved Naglazyme in January 2006. Naglazyme is a replacement therapy that is intended to provide exogenous enzyme and the clinical trials and usage experience thereafter have proved its efficacy for MPS VI. AnGes will pay upfront and will make milestone payments to BioMarin. However, those financial impacts are minimum. Copyright [c] 2007 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion